Botco.ai is the Enterprise AI Agent Platform purpose-built for organizations that need to engage customers through intelligent, reliable, and secure AI conversations. The platform enables enterprises to seamlessly create, securely deploy, and easily manage autonomous AI agents using a no-code development environment (IDE) and retrieval-augmented generation (RAG) technology. Trusted by leading healthcare, behavioral health, and pharmaceutical organizations, Botco.ai empowers businesses to convert conversations into revenue, reduce operational costs, and improve customer satisfaction. Recognized as “Most Outstanding Startup” by the Arizona Innovation Challenge and winner of the TiE50 and ACA Best SaaS Platform awards, Botco.ai is redefining how enterprises engage with their audiences through agentic AI.To learn more, visit www.botco.ai.
-
Share
Now -
-
-
-
Transforming Oncology Care with AI: Clinical Trial Matching and Patient Support in Action
Rebecca Clyde, CEO, Botco.ai | Dana M. Chase, Prof. of Clinical Obstetrics and Gynecology, UCLA Health
March 24, 2026 | 11:00am
How can AI improve oncology care in measurable ways without adding complexity to clinical workflows? Join Rebecca Clyde, CEO of Botco.ai, and Dr. Dana Chase, Professor of Gynecological Oncology at UCLA Health, for a practical discussion on how AI-powered tools are being deployed to improve patient engagement, symptom management, and clinical trial access in gynecologic oncology.
This session will spotlight two real-world implementations being studied at UCLA Health:
• AskGRACE — a 24/7 AI-enabled patient support companion that provides evidence-based guidance for symptom management, drug safety, and prognosis education, with bilingual support and immediate escalation for serious symptoms
• OncoTrial Match™ — an AI-powered clinical trial matching tool that identifies nearby recruiting trials and automates referrals in under 90 seconds through a secure, SMS-based interface Operational and Clinical Insights • How UCLA Health is applying AI in gynecologic oncology across patient engagement and clinical trial workflows while the studying impact on accrual rates and patient Quality of Life metrics
• How 24/7 conversational AI can support oncology patients between visits while maintaining structured escalation pathways
• How AI-powered trial matching can reduce referral friction and surface eligible studies in under 90 seconds, increasing accrual rates and reducing disparities in trial participation
• Practical insights into governance, compliance, clinician adoption, and workflow integration in real-world oncology settings
SPEAKERS
Rebecca Clyde | CEO, Botco.ai
Rebecca Clyde is the Co-founder and CEO of Botco.ai, which revolutionizes the way pharma and healthcare organizations improve patient outcomes with clinically validated AI agents. She is an accomplished entrepreneur and AI innovation leader who previously founded a leading digital agency and spent nearly a decade commercializing advanced technology at Intel. With an MBA from W.P. Carey School of Business and executive education from Stanford, she has been recognized as one of Arizona’s Most Influential Women. Under her leadership, Botco.ai received Google for Startups funding for its groundbreaking work applying generative AI in healthcare resulting in improved patient outcomes.
Dr. Dana M. Chase | Professor of Clinical Obstetrics and Gynecology, UCLA Health
Dr. Dana Chase is a Professor of Clinical Obstetrics and Gynecology at UCLA Health and a board-certified gynecologic oncologist and surgeon. She completed her medical degree, residency in obstetrics and gynecology, and fellowship in gynecologic oncology at the University of California, Irvine. Dr. Chase’s clinical and research interests include clinical trials in gynecologic cancers, chemotherapy, quality of life and patient-reported outcomes, survivorship, health disparities, and geriatric oncology. She is actively involved in advancing patient-centered cancer care and improving access to innovative treatment options. Dr. Chase speaks English and Spanish.